Stayin' alive: BCL-2 proteins in the hematopoietic system.

Autor: Zehnle PMA; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center of Freiburg, Freiburg, Germany; Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, University Medical Center of Freiburg, Freiburg, Germany., Wu Y; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center of Freiburg, Freiburg, Germany., Pommerening H; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center of Freiburg, Freiburg, Germany., Erlacher M; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center of Freiburg, Freiburg, Germany. Electronic address: miriam.erlacher@uniklinik-freiburg.de.
Jazyk: angličtina
Zdroj: Experimental hematology [Exp Hematol] 2022 Jun; Vol. 110, pp. 1-12. Date of Electronic Publication: 2022 Mar 18.
DOI: 10.1016/j.exphem.2022.03.006
Abstrakt: BH3 mimetics constitute a novel concept of antitumor therapy, inducing apoptosis via inhibition of pro-survival BCL-2 proteins. Programmed cell death is fundamental for physiological hematopoiesis; hence hematological side effects of these compounds are conceivable. Navitoclax and venetoclax have been studied extensively in the clinical setting; our knowledge of the more recently developed BCL-2 protein inhibitors specifically targeting MCL-1 or BCL-X L , however, is restricted mainly to preclinical experiments. To delineate possible adverse effects of novel BH3 mimetics on the human hematopoietic system, this review summarizes current knowledge of the function of specific antiapoptotic BCL-2 proteins in physiological hematopoiesis.
(Copyright © 2022 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: